Cancer Biology

Cancer remains one of the most pressing challenges in human health, driving decades of research into its complex biology and therapeutic strategies. Since the development of the first chemotherapies in the 1940s, cancer research has increasingly shifted toward targeted approaches. Today, cancer immunotherapy such as blockade of immune checkpoint proteins (CTLA-4, PD-1/PD-L1) and inhibition of tumor migration pathways offers new hope for effective treatment.

Bio X Cell supports cancer research with a comprehensive portfolio of antibodies, buffers, and isotype controls designed to study cancer-related targets and pathways. Each antibody is specifically formulated for sensitive in vivo and translational studies including in vitro organoid and organ-on-chip workflows, and is free from preservatives, stabilizers, and carrier proteins. With purity ≥95% and endotoxin levels as low as ≤0.5 EU/mg, functional antibodies from Bio X Cell provide reproducible, high-quality results across diverse cancer models.

Bio X Cell’s continuously expanding antibody catalog covers a broad range of cancer-associated antigens, including immune checkpoint ligands and receptors, co-stimulatory proteins, cytokines and cytokine receptors, and adhesion molecules. These antibodies are trusted tools for identifying cancer-driving targets and advancing preclinical studies toward breakthrough therapies.